EGFR and neoplasm: To rely on a previous report of tumor accumulation potential of the anti-EGFR Nanofitin B10 [13], tumor accumulation of the bispecific B10–B11 Nanofitin was monitored similarly in this study using the A431 tumor xenograft model.